The US Food and Drug Administration (FDA) has approved Wright Medical Group’s hip resurfacing system to give surgeons an alternative to hip replacement therapy.

The Conserve Plus Total Hip Resurfacing System, available in the US, provides surgeons and patients with a bone-conserving alternative to traditional total hip replacement, the company said.

Wright will be able to initiate efforts to introduce additional enhancements to the system, which at the moment are available only outside the US.

Hip resurfacing could be used for young active patients in need of surgical treatment for chronic pain, the company said.

The system is designed to offer pain relief and restoration of function, simultaneously retaining as much healthy bone as possible and preserving future surgery options, Wright said.